Loading company…
Teclens develops corneal cross-linking technologies and devices for vision correction and eye conditions.
Founded in 2013, Teclens develops crosslinking technology for keratoconus and vision correction. Its qCXL technology and CXLens device use patterned ultraviolet light and ultrasound to measure changes in corneal biomechanics. The company is based in Stamford, US. In August 2026, it raised USD 10 million in Series A funding from Johnson & Johnson Innovation, as part of a larger USD 19.3 million round.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in